Leber Congenital Amaurosis Market to Expand at a Significant Growth Rate During the Forecast Period (2022-32) - Estimates DelveInsight | ProQR Therapeutics, IVERIC bio, MeiraGTx, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies

As per DelveInsight, the Leber Congenital Amaurosis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Leber congenital amaurosis patients in the 7MM and the launch of new therapies in the market.

DelveInsight's "Leber Congenital Amaurosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Leber Congenital Amaurosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Leber Congenital Amaurosis market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Leber Congenital Amaurosis: An Overview
Leber congenital amaurosis (LCA) is a rare inherited eye disorder that causes severe vision loss at birth. The disease primarily affects the retina and is the most common cause of inherited blindness in childhood.

LCA is inherited in an autosomal recessive manner, meaning that both parents must carry a defective gene for the condition to pass it on to children. There is a 25% chance of inheriting the two LCA genes (one from each parent) needed to cause the disorder.

Babies born with LCA have a very reduced vision that can often be detected by parents in the first few months of life. They may not respond to visual cues and have roving eye movements, called nystagmus. Many children with LCA habitually press their eyes with their fists or fingers, which causes their eyes to look sunken or deep-set.

Leber Congenital Amaurosis Market Key Facts
According to National Organization for Rare Disorders (NORD, 2021), the prevalence of Leber congenital amaurosis (LCA) has been estimated to be 1-2 per 100,000 births.
According to Coussa et al. (2017), LCA is the second most common group of inherited retinal dystrophies after retinitis pigmentosa, accounting for about 5% of all retinal dystrophies. With an estimated prevalence ranging from 1 per 33,000 to 1 per 81,000, LCA was reported to account for about 20% of legal blindness in children.
Genetic and Rare Diseases Information Center (2021) estimated that the number of people with LCA in the US is between 3,000 and 30,000.
As per American Association for Pediatric Ophthalmology & Strabismus (2022), LCA is rare (2-3 cases per 100,000 births); about 10-18% of all cases of congenital blindness or severely reduced vision in children are caused by LCA.
Leber congenital amaurosis market dynamics are anticipated to change in the coming years due to the development of emerging therapies. Key players such as ProQR Therapeutics, Atsena Therapeutics, and others are actively working in the Leber Congenital Amaurosis Market.

Leber Congenital Amaurosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Leber Congenital Amaurosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Leber Congenital Amaurosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Leber Congenital Amaurosis Market will Grow by 2032:
https://www.delveinsight.com/report-store/leber-congenital-amaurosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Leber Congenital Amaurosis Epidemiology
The epidemiology section covers detailed insights into the historical and current Leber Congenital Amaurosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Leber Congenital Amaurosis Epidemiology Segmented as -
Total Prevalent cases of Leber Congenital Amaurosis in the 7MM [2019-2032]
Gene-specific cases of Leber Congenital Amaurosis in the 7MM [2019-2032]
Total Diagnosed Prevalent cases of Leber Congenital Amaurosis in the 7MM [2019-2032]
Treatable cases of Leber Congenital Amaurosis in the 7MM [2019-2032]

Get Key Insights Into the Evolving Leber Congenital Amaurosis Epidemiology Trends:
https://www.delveinsight.com/report-store/leber-congenital-amaurosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Leber Congenital Amaurosis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Leber Congenital Amaurosis market or expected to be launched during the study period. The analysis covers Leber Congenital Amaurosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Leber Congenital Amaurosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Leber Congenital Amaurosis Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Leber Congenital Amaurosis. Currently, ProQR Therapeutics is leading the therapeutics market with its Leber Congenital Amaurosis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Leber Congenital Amaurosis Therapeutics Market Include:
ProQR Therapeutics
Editas Medicine
Atsena Therapeutics Inc.
Applied Genetic Technologies Corporation
IVERIC bio
MeiraGTx
And Many Others

Leber Congenital Amaurosis Emerging and Marketed Drugs Covered in the Report Include:
Sepofarsen (QR-110): ProQR Therapeutics
EDIT-101: Editas Medicine, Inc.
Luxturna: Spark Therapeutics
ATSN-101: Atsena Therapeutics
And Many More

Learn More About the Emerging Therapies & Key Companies in the Leber Congenital Amaurosis Therapeutics Market:
https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Leber Congenital Amaurosis Competitive Intelligence Analysis
4. Leber Congenital Amaurosis Market Overview at a Glance
5. Leber Congenital Amaurosis Background and Overview
6. Leber Congenital Amaurosis Patient Journey
7. Leber Congenital Amaurosis Epidemiology and Patient Population
8. Leber Congenital Amaurosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Leber Congenital Amaurosis Unmet Needs
10. Key Endpoints of Leber Congenital Amaurosis Treatment
11. Leber Congenital Amaurosis Marketed Products
12. Leber Congenital Amaurosis Emerging Therapies
13. Leber Congenital Amaurosis Seven Major Market Analysis
14. Attribute Analysis
15. Leber Congenital Amaurosis Market Outlook (7 major markets)
16. Leber Congenital Amaurosis Access and Reimbursement Overview
17. KOL Views on the Leber Congenital Amaurosis Market.
18. Leber Congenital Amaurosis Market Drivers
19. Leber Congenital Amaurosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Reports by DelveInsight-)
- Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

- Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

- Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

- Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market

- Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

- Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

- Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market

- Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

- Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market

- Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market

- Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

- Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market

- Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

- Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.